Search results for "lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens"

showing 10 items of 382 documents

Developments in esophageal surgery for adenocarcinoma: a comparison of two decades

2007

Abstract Background The objective of this study was to examine outcomes in patients undergoing esophageal resection for adenocarcinoma at our institution during a 20-year period and, in particular, to address temporal trends in long-term survival. Methods Out of 470 patients who underwent esophagectomy for malignancy between September 1985 and September 2005, a total number of 175 patients presented with esophageal adenocarcinoma. Patients enrolled in this study included AEG (adenocarcinoma of the esophagogastric junction) type I tumors only. Time trends were studied comparing two decades, 9/1985 to 9/1995 (DI) and 10/1995 to 9/2005 (DII). Results The overall survival was significantly more…

AdultMalemedicine.medical_specialtyCancer ResearchTime FactorsEsophageal Neoplasmsmedicine.medical_treatmentAdenocarcinomaMalignancylcsh:RC254-282Disease-Free SurvivalSurgical oncologymedicineGeneticsHumansSurvivorsEsophagusSurvival analysisAgedNeoplasm StagingRetrospective Studiesbusiness.industryRetrospective cohort studyMiddle AgedPrognosislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseCombined Modality TherapySurvival AnalysisSurgeryEsophagectomyLog-rank testTreatment Outcomemedicine.anatomical_structureOncologyEsophagectomyLymph Node ExcisionAdenocarcinomaFemalebusinessResearch ArticleBMC Cancer
researchProduct

Population-based study of ovarian cancer in Côte d'Or: prognostic factors and trends in relative survival rates over the last 20 years

2010

Abstract Background The aim of this population-based study was to assess independent prognostic factors in ovarian cancer using relative survival (RS) and to investigate changes in RS rates from 1982 to 2005. Methods Data on 748 patients with ovarian cancer were provided by the Côte d'Or gynaecologic cancer registry. The RS was estimated using a generalized linear model with a Poisson error structure. Relative survival and its 95% confidence interval (CI) were described at the following specific time points 1, 3 and 5 years. The effect of prognostic factors on survival was assessed with multivariate analyses of RS. Results The median follow-up was 12 years. The RS rates at 1, 3 and 5 years …

AdultOncologymedicine.medical_specialtyCancer ResearchMultivariate analysisAdolescentPopulationMedical Oncologylcsh:RC254-282Internal medicinemedicineGeneticsHumansRegistriesChildeducationSurvival rateAgedAged 80 and overOvarian NeoplasmsGynecologyeducation.field_of_studyRelative survivalbusiness.industryCancerMiddle AgedPrognosislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseConfidence intervalSurvival RateSerous fluidTreatment OutcomeOncologyFemaleFranceOvarian cancerbusinessResearch ArticleBMC Cancer
researchProduct

For patients with breast cancer, geographic and social disparities are independent determinants of access to specialized surgeons. A eleven-year popu…

2012

Abstract Background It has been shown in several studies that survival in cancer patients who were operated on by a high-volume surgeon was better. Why then do all patients not benefit from treatment by these experienced surgeons? The aim of our work was to study the hypothesis that in breast cancer, geographical isolation and the socio-economic level have an impact on the likelihood of being treated by a specialized breast-cancer surgeon. Methods All cases of primary invasive breast cancer diagnosed in the Côte d’Or from 1998 to 2008 were included. Individual clinical data and distance to the nearest reference care centre were collected. The Townsend Index of each residence area was calcul…

AdultRural PopulationCancer Researchmedicine.medical_specialtyGeographical isolationBreast Neoplasms[SDV.CAN]Life Sciences [q-bio]/CancerPopulation basedlcsh:RC254-282Health Services Accessibility[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicineBreast cancer[SDV.CAN] Life Sciences [q-bio]/CancerSurgical oncologyGeneticsmedicineHumans030212 general & internal medicineRegistriesHealthcare DisparitiesAgedNeoplasm StagingGynecologybusiness.industryMultilevel modelCancerMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePrognosis3. Good healthsurgical procedures operativeOncologySocioeconomic Factors030220 oncology & carcinogenesisFamily medicineMultilevel AnalysisNeoplasm stagingFemalebusinessRural populationResearch Article
researchProduct

An active form of sphingosine kinase-1 is released in the extracellular medium as component of membrane vesicles shed by two human tumor cell line.

2010

Expression of sphingosine kinase-1 (SphK-1) correlates with a poor survival rate of tumor patients. This effect is probably due to the ability of SphK-1 to be released into the extracellular medium where it catalyzes the biosynthesis of sphingosine-1-phosphate (S1P), a signaling molecule endowed with profound proangiogenic effects. SphK-1 is a leaderless protein which is secreted by an unconventional mechanism. In this paper, we will show that in human hepatocarcinoma Sk-Hep1 cells, extracellular signaling is followed by targeting the enzyme to the cell surface and parallels targeting of FGF-2 to the budding vesicles. We will also show that SphK-1 is present in a catalitycally active form i…

Article SubjectNeutral CeramidasebiologySphingosineVesicleCellmembrane vesicleslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensSphK vesicleslcsh:RC254-282Cell biologychemistry.chemical_compoundmedicine.anatomical_structureOncologySphingosine kinase 1chemistryBiosynthesisCell cultureSettore BIO/10 - Biochimicabiology.proteinExtracellularmedicinesphingosine kinase; ceramidase; tumoe cells. microvesiclesResearch Article
researchProduct

PSA and PSA Kinetics Thresholds for the Presence of 68Ga-PSMA-11 PET/CT-Detectable Lesions in Patients with Biochemical Recurrent Prostate Cancer

2020

68Ga-PSMA-11 positron-emission tomography/computed tomography (PET/CT) is commonly used for restaging recurrent prostate cancer (PC) in European clinical practice. The goal of this study is to determine the optimum time for performing these PET/CT scans in a large cohort of patients by identifying the prostate-specific-antigen (PSA) and PSA kinetics thresholds for detecting and localizing recurrent PC. This retrospective analysis includes 581 patients with biochemical recurrence (BC) by definition. The performance of 68Ga-PSMA-11 PET/CT in relation to the PSA value at the scan time as well as PSA kinetics was assessed by the receiver-operating-characteristic-curve (ROC) generated by plottin…

Biochemical recurrenceCancer Researchmedicine.medical_treatment68Gallium-PSMA PET/CTurologic and male genital diseaseslcsh:RC254-282030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicine<sup>68</sup>gallium-psma pet/ctprostate-specific-antigenPSA kinetics thresholdsbiochemical recurrenceMedicineoptimal cutoff levelPET-CTPsa kineticsbusiness.industryProstatectomylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensprostate cancermedicine.diseaseRadiation therapyProstate-specific antigenOncology030220 oncology & carcinogenesisRecurrent prostate cancerbusinessNuclear medicineCancers
researchProduct

Myeloid-Derived Suppressor Cells in Multiple Myeloma: Pre-Clinical Research and Translational Opportunities

2014

Immunosuppressive cells have been reported to play an important role in tumor-progression mainly because of their capability to promote immune-escape, angiogenesis, and metastasis. Among them, myeloid-derived suppressor cells (MDSCs) have been recently identified as immature myeloid cells, induced by tumor-associated inflammation, able to impair both innate and adaptive immunity. While murine MDSCs are usually identified by the expression of CD11b and Gr1, human MDSCs represent a more heterogeneous population characterized by the expression of CD33 and CD11b, low or no HLA-DR, and variable CD14 and CD15. In particular, the last two may alternatively identify monocyte-like or granulocyte-lik…

Cancer ResearchAngiogenesisCD33MDSCInflammationReview Articlelcsh:RC254-282Immune systemImmunesuppressionmedicinecancerimmunosuppressionbusiness.industryAcquired immune systemlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenspreclinical modelsmedicine.anatomical_structuremyelomaOncologyTumor progressionImmunologyMyeloid-derived Suppressor CellBone marrowmedicine.symptombusinesspre-clinical modelsFrontiers in Oncology
researchProduct

In the literature: February 2019

2019

Malignant pleural mesothelioma (MPM) is a rare and lethal cancer associated to asbestos exposure. Currently, the pemetrexed and cisplatin combination chemotherapy remains the only approved treatment. In the last 5 years, a growing knowledge on mesothelioma pathobiology has translated into the development of multiple novel therapeutic strategies.1 One of the largest reports of comprehensive genomic profiling of MPM was conducted by Bueno and colleagues. Using RNA-seq data, they identified four distinct molecular subtypes, and through exome analysis, they found that BAP1 , NF2 , TP53 , SETD2 , DDX3X , ULK2 , RYR2 , CFAP45 , SETDB1 and DDX51 were significantly mutated.2 In an article recently …

Cancer ResearchBAP1business.industryCombination chemotherapyNewslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaselcsh:RC254-282PemetrexedMRNA SequencingOncologySETD2DNA methylationCancer researchmedicine1506MesotheliomabusinessExomemedicine.drugESMO Open
researchProduct

Why do results conflict regarding the prognostic value of the methylation status in colon cancers? The role of the preservation method.

2012

Abstract Background In colorectal carcinoma, extensive gene promoter hypermethylation is called the CpG island methylator phenotype (CIMP). Explaining why studies on CIMP and survival yield conflicting results is essential. Most experiments to measure DNA methylation rely on the sodium bisulfite conversion of unmethylated cytosines into uracils. No study has evaluated the performance of bisulfite conversion and methylation levels from matched cryo-preserved and Formalin-Fixed Paraffin Embedded (FFPE) samples using pyrosequencing. Methods Couples of matched cryo-preserved and FFPE samples from 40 colon adenocarcinomas were analyzed. Rates of bisulfite conversion and levels of methylation of …

Cancer ResearchBisulfite sequencing[SDV.CAN]Life Sciences [q-bio]/CancerAdenocarcinomaBiologyMLH1lcsh:RC254-282[ SDV.CAN ] Life Sciences [q-bio]/Cancerchemistry.chemical_compound[SDV.CAN] Life Sciences [q-bio]/CancerPredictive Value of TestsBiomarkers TumorGeneticsHumansSulfitesDNA Modification MethylasesAdaptor Proteins Signal TransducingCryopreservationParaffin EmbeddingTumor Suppressor ProteinsNuclear ProteinsReproducibility of ResultsDNA NeoplasmMethylationDNA MethylationPrognosislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensMolecular biologydigestive system diseasesNeoplasm ProteinsBisulfiteDNA Repair EnzymesLong Interspersed Nucleotide ElementsPhenotypeOncologyCpG sitechemistrySodium bisulfiteColonic NeoplasmsDNA methylationFeasibility StudiesPyrosequencingCpG IslandsMutL Protein Homolog 1Research Article
researchProduct

In the literature: June 2020.

2020

Immunotherapy based on checkpoint blockade has revolutionised cancer treatment during last years. Whereas this approach fails in a relevant group of patients, the knowledge on tumour microenvironment (TME) opened the possibility to the use of additional therapeutic strategies to potentiate antitumour immunity, including depletion of protumourigenic or immune suppressive and activation of specific immune populations using agonistic antibodies. Nevertheless, due to the complexity of the TME, many of these strategies have been indiscriminately advanced to the clinic without clear mechanistic hypotheses. Nowadays, single-cell RNA sequencing (scRNA-seq)-based transcriptome analyses identify T ce…

Cancer ResearchCD40AngiogenesisT cellmedicine.medical_treatmentAntigen presentationImmunotherapyBiologyNewslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282not applicableImmune systemmedicine.anatomical_structureOncologyCancer cellbiology.proteinmedicineCancer research1506AntibodyESMO open
researchProduct

Targeting MYCN in Pediatric and Adult Cancers

2021

The deregulation of theMYCfamily of oncogenes, includingc-MYC,MYCNandMYCLoccurs in many types of cancers, and is frequently associated with a poor prognosis. The majority of functional studies have focused onc-MYCdue to its broad expression profile in human cancers. The existence of highly conserved functional domains betweenMYCNandc-MYCsuggests thatMYCNparticipates in similar activities.MYCencodes a basic helix-loop-helix-leucine zipper (bHLH-LZ) transcription factor (TF) whose central oncogenic role in many human cancers makes it a highly desirable therapeutic target. Historically, as a TF, MYC has been regarded as “undruggable”. Thus, recent efforts focus on investigating methods to indi…

Cancer ResearchCancercofactorReviewSynthetic lethalityMYCBiologymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPediatric cancerlcsh:RC254-282pediatric cancerOncologyTranscription (biology)MYCNCancer researchmedicinecancerFunctional studiesSuper-enhancer (SE)Transcription factorPsychological repressionN-Mycneoplasmstranscription factorFrontiers in Oncology
researchProduct